Scientists solve a drug shelf-life problem
Posted on: Wednesday, 8 July 2009, 15:36 CDT
Massachusetts Institute of Technology scientists say they've created a computer model that might solve the problem of some drugs having a short shelf life.
Researchers said the problem has plagued drug companies trying to develop medicines made of antibodies: The problem is that, over time, the antibodies tend to clump together, rendering the drugs ineffective.
Antibodies, the scientists said, are the most rapidly growing class of human drugs, with the potential to treat cancer, arthritis and other diseases. But the MIT researchers said there currently is no straightforward way to address the storage issue early in the development process.
Drugs are usually developed with the criteria of how effective they'll be, and how well they'll bind to whatever target they're supposed to bind,
said Professor Bernhardt Trout, who led the research. The problem is there are all of these issues down the line that were never taken into account.
Trout and his colleagues, including Bernhard Helk of the Novartis Pharmaceuticals Corp., have developed a computer model that can help designers identify the parts of an antibody most likely to attract other molecules, allowing them to alter the antibodies to prevent clumping.
The model, which the researchers aim to incorporate in the drug discovery process, is described in the Proceedings of the National Academy of Sciences.
Source: United Press International
Related Articles
- Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
- Seattle Genetics Presents Preclinical Data on Its Antibody-Drug Conjugate Technology and SGN-33 Program at AACR
- NSCLC Drug Market to Exceed $4 Billion Between 2010 and 2015 According to the Report 'Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC'
- New Report Compiles and Analyzes In Parallel the Progress Concerning Drug Development and Competitive Situation in Antibody Drug Targeting Focusing On Leukemia and Lymphoma
- 'Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- And Prostate Cancer' Provides a Framework and a Careful Evaluation of Drug Candidates, Technologies and Competitors
- In Depth Report Analyzes Three Major and Intertwined Areas of Cancer R&D Antibody Drug Target Leukemias and Lymphomas
- Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
- Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
- Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With CuraGen
- Faster method to create antibodies for disease research
User Comments (0)

RSS Feeds